• ASP Isotopes set a strategy to scale from buildout to production, targeting more than $300 million of EBITDA in 2031.
• Next 12 months focus on revenue lift from liquid helium output as Virginia Gas Phase 1 completes, supported by radiopharmacy growth.
• Stable isotope division aims to start first commercial shipments, expanding the customer base as commercialization begins.
• Planning continues to pursue separate public listings for Quantum Leap Energy, Noble Africa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ASP Isotopes Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080915PRIMZONEFULLFEED9822816) on September 08, 2026, and is solely responsible for the information contained therein.